Stimuli-responsive mesoporous silica nanoparticle-based drug delivery systems

Mesoporous silica nanoparticles (MSNs) are versatile inorganic nanocarriers whose ordered mesopores, high surface area, tunable pore dimensions, and modifiable surfaces permit loading and controlled release of diverse therapeutic cargos. This review evaluates stimuli-responsive MSN design through an explicit evidence-grading lens: each proposed trigger is considered in relation to the primary study, biological model, demonstrated response, and principal limitation. Endogenous cues include pH, glutathione/redox conditions, reactive oxygen species, enzymes, glucose, ATP, and hypoxia; exogenous triggers include temperature, light, magnetic fields, and ultrasound. These cues can be coupled to molecular gates, cleavable linkers, responsive polymers, charge-reversal systems, or hybrid components. The review considers MSN architectures, synthesis and template removal, surface functionalization, drug loading and release, characterization, biological evaluation, and biomedical applications. Particular attention is paid to the distinction between chemical responsiveness and biological selectivity, and between in vitro , ex vivo , animal, and clinical evidence. Translational constraints include protein-corona formation, biological heterogeneity, biodistribution, intracellular trafficking, residual template or surfactant, sterilization, batch reproducibility, scale-up, and regulatory complexity. Emerging biodegradable and biomimetic MSNs, nucleic-acid delivery, theranostics, precision nanomedicine, and data-assisted formulation development are treated as developing rather than uniformly established technologies. The review’s contribution is a comparative framework for asking whether each added responsive function produces a measurable benefit over a simpler carrier, rather than assuming that greater structural complexity improves therapeutic performance. The evidence-based framework used here distinguishes the level of testing from the strength of the claim: in vitro release or cell data establish proof of concept, ex vivo data address selected tissue-level behavior, animal studies provide preclinical evidence, and clinical evidence requires human evaluation of the specific responsive MSN system. Clinical experience with other silica-containing materials is not equivalent to clinical validation of stimuli-responsive MSN drug carriers. Key translational questions include predictable degradation and clearance, control of manufacturing-related impurities, reproducible critical quality attributes, clinically relevant trigger intensity, and demonstrated safety and efficacy in appropriate models.